Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Eli Lilly shares rose nearly 1.6% on Wednesday morning to three-week highs after the company unveiled promising results from ...

Eli Lilly (LLY) stock is rising after the company said its weight-loss drug achieved better results than Wegovy ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...

Tiger Global Management's 13F portfolio increased to $23.44B. Check out the notable increases, decreases, and new stakes of ...

Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing ...

Investing.com -- Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo Nordisk (NYSE: NVO )'s Wegovy (semaglutide) in the phase 3b ...